Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics (Nasdaq: KPTI) reported that it granted an aggregate of 1,850 restricted stock units (RSUs) to two newly hired employees as of August 31, 2026.

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) reported that it granted an aggregate of 1,850 restricted stock units (RSUs) to two newly hired employees as of August 31, 2026. The awards were issued under the company’s 2022 Inducement Stock Incentive Plan, as inducement grants in line with Nasdaq Listing Rule 5635(c)(4).

Each RSU award vests over three years, with 33 1/3% of the shares vesting on each anniversary of the grant date, subject to the employee’s continued service with Karyopharm.

Argus Sep 2 session 15 alerts

-4.32% close to close 1.4x rel. volume Open Argus

Details

Market move: KPTI -4.32% in the Sep 2 session. inducement equity grant

-10.6% Trough in 7 hr 51 min

$44.00M Mkt Cap at Peak Alert

On Sep 2, the first trading day after this news, KPTI closed 4.32% below the previous close. Argus tracked a trough of -10.6% from its starting point during tracking. Our momentum scanner recorded 15 alerts for this stock that day.

Data tracked by StockTitan Argus for the Sep 2 session.

Key Figures

RSU Grant: 1,850 restricted stock units Recipients: 2 employees Grant Date: August 31, 2026 +2 more

RSU Grant

1,850 restricted stock units

Aggregate award to two newly hired employees

Recipients

2 employees

Newly hired employees receiving the aggregate grant

Grant Date

August 31, 2026

Date the RSU awards were granted

Vesting Period

3 years

Each RSU award vests over three years

Annual Vesting

33 1/3%

Shares vesting on each of three consecutive anniversaries

Historical Context

5 past events · Latest: Aug 31

5 events

1. Aug 31

   sNDA submission

   24h Move

   +10.2%

   Submitted sNDA seeking accelerated approval for myelofibrosis treatment

2. Aug 13

   2Q26 earnings

   24h Move

   -1.7%

   Reported net loss and financing pressure despite reaffirmed revenue guidance

3. Aug 10

   Earnings date notice

   24h Move

   -7.5%

   Scheduled second-quarter financial results for August 13, 2026

4. Aug 03

   Inducement grant

   24h Move

   -0.5%

   Granted 333 restricted stock units to a newly hired employee

5. Jul 30

   sNDA plans

   24h Move

   -72.6%

   Planned accelerated-approval submission supported by Phase 3 SENTRY data

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of August 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

CONTACT:
Brendan Strong
Senior Vice President, Investor Relations
617.762.2661
brendan.strong@karyopharm.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302862411.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity grants did Karyopharm Therapeutics (KPTI) announce on September 1, 2026?

Karyopharm Therapeutics granted an aggregate of 1,850 RSUs to two newly hired employees. According to Karyopharm, these restricted stock units were granted on August 31, 2026 under its 2022 Inducement Stock Incentive Plan as material inducements to employment.

How do the new Karyopharm (KPTI) inducement RSUs vest for employees?

The new Karyopharm RSU awards vest over three years in equal annual installments. According to Karyopharm, 33 1/3% of each award vests on each of the three consecutive anniversaries of the August 31, 2026 grant date, subject to continued service.

Under which plan were Karyopharm Therapeutics (KPTI) inducement RSUs granted in August 2026?

The inducement RSUs were granted under Karyopharm’s 2022 Inducement Stock Incentive Plan, as amended. According to Karyopharm, this plan is used specifically for inducement awards that are material to new employees joining the company, consistent with Nasdaq Listing Rule 5635(c)(4).

Why did Karyopharm (KPTI) use Nasdaq Listing Rule 5635(c)(4) for these RSU grants?

Karyopharm used Nasdaq Listing Rule 5635(c)(4) to grant RSUs as material inducements for new hires. According to Karyopharm, these equity awards are specifically tied to the employees entering into employment and are structured as non-shareholder-approved inducement grants under Nasdaq rules.

What employment conditions affect vesting of Karyopharm Therapeutics (KPTI) August 31, 2026 RSU awards?

The RSU awards vest only if the recipients maintain ongoing service with Karyopharm. According to Karyopharm, vesting is conditioned on each employee’s continued employment or other qualifying service with the company through the applicable three annual vesting dates after the grant date.